Technologies
PDF


WARF: P140372US02

Xeno-Free Protocol for Generating Endothelial Cells from Human Pluripotent Stem Cells


INVENTORS -

James Thomson, Jue Zhang

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing the first fully defined method of its kind to derive human endothelial cells suitable for clinical applications.
OVERVIEWEndothelial cells (ECs) are vital to blood vessel formation. Generating ECs from human pluripotent stem cells (hPSCs) has powerful potential for cardiovascular health and drug development. However, standard protocols use xenogenic (animal-derived) reagents such as bovine serum albumin that are often poorly defined, pose safety concerns for clinical applications and contribute to highly variable results and limited reproducibility.
THE INVENTIONUW–Madison researchers have developed a fully defined and xenogenic material-free method of producing and expanding clinically relevant human ECs for therapeutic and tissue modelling applications. Populations of up to 80 percent CD31+ ECs are generated from both human embryonic and induced pluripotent stem cells.

Like existing protocols, the new method uses factors including Bone Morphogenetic Protein (BMP), Activin A and a TGF-Beta 1 inhibitor.
APPLICATIONS
  • Generation of clinical grade endothelial cells
  • Potential applications include engineering of new blood vessels, EC transplantation into the heart, myocardial regeneration, treatment of regional ischemia, drug and toxicity screening
KEY BENEFITS
  • First xeno-free, albumin-free, fully chemically defined method of its kind
  • Highly efficient and reproducible
STAGE OF DEVELOPMENTThe protocol has been shown to generate 50-80 percent CD31+ ECs depending on the cell line. The results demonstrate robust and efficient generation of human ECs in fully defined conditions, which addresses a crucial production requirement for potential clinical utility.
Contact Information
For current licensing status, please contact Andy DeTienne at adetienne@warf.org or (608) 262-7859.
The WARF Advantage

Since its founding in 1925 as the patenting and licensing organization for the University of Wisconsin-Madison, WARF has been working with business and industry to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.